Silexion Therapeutics (NASDAQ:SLXN) announced positive preclinical data for its pancreatic cancer drug SIL204. The study demonstrated that subcutaneously administered SIL204 successfully reached major pancreatic cancer metastatic sites and showed anti-tumor activity.
Key findings include successful drug distribution to liver, peritoneum, and lung following a single subcutaneous injection at 5mg/mouse, with statistically significant reductions (p<0.01) in tumor burden observed in the peritoneum, lung, and intestine. The results validate the systemic component of Silexion's dual-route administration strategy.
The company remains on track to initiate Phase 2/3 clinical trials in H1 2026, with regulatory submissions planned for Q4 2025 and Q1 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.